Impact of triple antithrombotic therapy with warfarin or dual antithrombotic therapy with dabigatran according to the baseline bleeding risk. Results for the primary endpoint. Hazard ratios (HRs) and 95% CIs from Cox proportional hazard model; stratified by age (elderly vs. nonelderly) for dabigatran 110 mg dual therapy vs. warfarin triple therapy; unstratified for dabigatran 150 mg dual therapy vs. warfarin triple therapy. *For the comparison with 150 mg dabigatran DAT, elderly patients outside USA are excluded. DAT, dual antithrombotic therapy; MBE, major bleeding events; PD, PRECISE-DAPT score; TAT, triple antithrombotic therapy.